Phase 2 N=36 Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cetuximab — 750 mg/m^2 every 21 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=189 A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.
Anemia
Primary: Mean Change in Hemoglobin Concentration From Baseline to Week 16 of the Treatment Period — 2.11 gram/deciliter (g/dL) — p=<0.0001
N/A N=5 Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients
Obesity
Primary: Fat Absorption — 60.6 g/d — p=<0.05
Phase 2 N=50 Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Maximum Change From Baseline in QTc Interval Based on the Fridericia Correction (QTcF) Method — -1.4 millisecond (msec)
N/A N=30 Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Change in Hamilton Depression Rating Scale (HAM-D 17) Score From Baseline to Week 3 — 14.8; 13.6 units on a scale
Phase 2 N=8 Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression
Diabetes Mellitus, Type 1
Primary: The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation — 5 participants
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
Phase 2 N=35 Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
Opiate Dependence
Primary: Retention in Treatment — 26 participants
Phase 2 N=62 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Ovarian Cancer
Primary: PFS — 29.8 Months
Phase 2 N=119 Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Carcinoma, Non-small Cell
Primary: Progression-Free Survival (PFS) at Month 4: Cohort A — 76.9 percentage of participants
Phase 3 N=547 A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants With Remission at Week 8 — 16.6; 3.6 percentage of participants — p=0.0005
N/A N=272 Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
Malignant Neoplasm of Breast Stage IV
Primary: Progression Free Survival — 10.6 month
Phase 4 N=8 NMDA Antagonists in Bipolar Depression
Bipolar Disorder
Primary: Hamilton Depression Rating Scale (HAM-D) — 9.5 units on a scale (final score) — p=<0.001
N/A N=4 Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
Ulcerative Colitis
Primary: Change From Baseline of Mucus Production at 12 Weeks and 24 Weeks as Assessed by Histopathology
N/A N=41 Clinical and Radiographic Evaluation of Demineralized Freeze-Dried Bone Allograft Versus Platelet Rich Fibrin for the Treatment of Periodontal Intrabony Defects in Humans
Periodontitis
Primary: Change in Clinical Attachment Level (CAL) — 1.21; 1.03 mm